AstraZeneca PLC

NYSE:AZN

Drug Manufacturers - General

Healthcare
$178.76 -1.71%

-$3.04 today

Market cap
$277.23B
Beta
0.21
P/E (TTM)
25.7
EPS (TTM)
$6.75
Dividend yield
1.80%
52W Low $137.22High $212.71

Volume 2.54M

Average 1.96M

AZN Common Stock Repurchased

Cash spent buying back the company's own shares.

AstraZeneca PLCNYSE: AZN

Common Stock Repurchased · Q3 FY2026 · quarter ended Sep 2026

Common stock repurchased grows, but more slowly than its trailing trend

Q3 FY2026 common stock repurchased of $103.69M (cash outflow) rose 710.0% year over year, behind the +2624.7% change in trailing-twelve-month common stock repurchased. Sequentially, it rose 123.8% from the prior quarter.

Context

  • Common stock repurchased amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Common stock repurchased increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +710.0% toward the trailing-twelve-month pace of +2624.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$103.69M+123.8% QoQ
Last fiscal yearDec 2025
$0— YoY
LTMSep 2026
-$348.8M+2624.7% YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+710.0%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Common Stock Repurchased vs competitors

How AZN compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock repurchased is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +2624.7% is the highest of 8, against a peer median of +22.2%.
  • Common stock repurchased amounts to 0.6% of revenue for AZN, versus a peer median of 2.3%.
AZN Competitors
Common Stock Repurchased for AZN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$7.88B USD+82.8%-0.5%7.9%
NVSNovartis AGLTM Jun 2026$6.85B USD-38.0%-4.6%12.3%
LLYEli Lilly and CompanyLTM Jun 2026$6.17B USD+40.5%+39.9%7.7%
NVONovo Nordisk A/SLTM Jun 2026DKK 5.9B DKK-47.7%-61.4%1.8%
MRKMerck & Co., Inc.LTM Jun 2026$4.21B USD+22.2%—6.3%
ABBVAbbVie Inc.LTM Jun 2026$1.51B USD+11.6%-13.0%2.3%
AZNAstraZeneca PLCLTM Sep 2026$348.8M USD+2624.7%—0.6%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$98M USD——0.2%
AMGNAmgen Inc.LTM Jun 2026$0 USD+100.0%—0.0%
PFEPfizer Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding AZN) —+22.2%-4.6%2.3%

Competitors are the stored peer set for AZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(265M)2.5B6.9B8.69B10.23B
Depreciation & Amortization4.1B5.25B4.93B5.07B5.73B
Deferred Income Tax(615M)(619M)000
Stock-Based Compensation615M619M579M00
Change in Working Capital2.02B3.76B300M(893M)(1.16B)
Accounts Receivables(961M)(1.35B)(1.43B)(1.62B)0
Inventory1.58B3.94B(669M)(131M)0
Accounts Payables961M1.35B1.43B00
Other Working Capital444M(184M)969M862M(1.16B)
Other Non-Cash Items105M(1.7B)(2.37B)(1B)(220.71M)
Operating Cash Flow5.96B9.81B10.35B11.86B14.58B
Capital Expenditures(2.2B)(2.57B)(3.78B)(4.59B)(5.91B)
Acquisitions (Net)(9.43B)(1.06B)(1.18B)(3.93B)(1.24B)
Purchases of Investments(184M)(159M)(136M)(96M)(229M)
Sales of Investments105M42M129M108M131M
Other Investing Activities654M789M(1.52B)(2.14B)(2.66B)
Investing Cash Flow(11.06B)(2.96B)(4.06B)(7.98B)(6.81B)
Debt Repayment7.89B(1.2B)(965M)1.81B(1.65B)
Common Stock Issued29M29M33M(43M)(481M)
Common Stock Repurchased00000
Dividends Paid(3.86B)(4.36B)(4.48B)(4.63B)(4.97B)
Other Financing Activities(418M)(1.29B)(1.15B)(1.13B)(442M)
Financing Cash Flow3.65B(6.82B)(6.57B)(4B)(7.54B)
Effect of Forex Changes(62M)(80M)(60M)(93M)46M
Net Change in Cash(1.51B)(55M)(346M)(208M)269M
Free Cash Flow3.76B7.24B6.57B7.28B8.67B

AstraZeneca PLC

NYSE:AZN

Intrinsic Alpha fair value

Locked

Current Price

$178.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.